Document is current

Article History

Received: 18 January 2021

Accepted: 29 April 2021

First Online: 29 May 2021

Declarations

:

: Written informed consent was obtained from all patients participating in the study. The local ethics committees approved the study protocol in accordance with the Declaration of Helsinki (1964) in its currently applicable version.

: Not applicable.

: J. Havla reports grants for OCT research from the Friedrich-Baur-Stiftung and Merck; personal fees and non-financial support from Celgene, Merck, Alexion, Novartis, Roche, Santhera, Biogen, Heidelberg Engineering, and Sanofi Genzyme; and non-financial support of the Guthy-Jackson Charitable Foundation, all outside the submitted work.T. Pakeerathan has no conflicts of interest.C. Schwake has no conflicts of interest.J.L. Bennett reports payment for study design/consultation from MedImmune/Viela Bio; personal fees from AbbVie, Alexion, Chugai, Clene Nanomedicine, Mitsubishi-Tanabe, Reistone Bio, Genentech, and Roche; grants and personal fees from Novartis, Mallinckrodt, and the National Institutes of Health; and has a patent for Aquaporumab issued.I. Kleiter has received speaker honoraria or travel funding from Alexion, Biogen, Novartis, Merck, Mylan, Sanofi Genzyme, and Roche; travel funding from the Guthy-Jackson Charitable Foundation; and consulted for Alexion, Biogen, Celgene, Chugai, IQVIA, Novartis, Merck, and Roche.A. Felipe-Rucián has no conflicts of interest.S.C. Joachim received travel funding and/or speaker honoraria from Bayer, Novartis, and Roche and received research support from Bayer, Novartis, Roche, and Ursapharm.A. S. Lotz-Havla has received travel expenses from BioMarin.T. Kümpfel received speaker and/or consultation honoraria from Bayer Healthcare, Merck, Novartis Pharma, Roche Pharma, and Biogen as well as grant support from Novartis.M. Krumbholz received travel funding and/or speaker honoraria from Merck, Novartis, and Roche and research support from Merck.E. Wendel has nothing to declare.M. Reindl (the University Hospital and Medical University of Innsbruck (Austria); employer of M. Reindl) receives payments for antibody assays (MOG, AQP4, and other autoantibodies) and for antibody validation experiments organized by Euroimmun and research grants from Euroimmun and Roche.C. Thiels has no conflicts of interest.T. Lücke has no conflicts of interest.K. Hellwig has received travel grants from Biogen, Novartis, and Merck and received speaker and research honoraria from Biogen Idec Germany, Teva, Sanofi Genzyme, Novartis, Bayer Healthcare, Merck Serono, and RocheR. Gold received speaker’s and board honoraria from Baxter, Bayer Schering, Biogen Idec, CLB Behring, Genzyme, Merck Serono, Novartis, Stendhal, Talecris, and Teva. His department received grant support from Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Novartis, and Teva. All are not related to the content of this manuscript.K. Rostasy has no conflict of interest related to this article.I. Ayzenberg has received travel grants from Biogen Idec and Guthy-Jackson Charitable Foundation, served on scientific advisory boards for Roche and Alexion, and received research support from Diamed, not related to this manuscript.